Abstract:Abstract Cancer biomarkers have transformed current practices in the oncology clinic. Continued discovery and validation are crucial for improving early diagnosis, risk stratification, and monitoring patient response to treatment. Profiling of the tumour genome and transcriptome are now established tools for the discovery of novel biomarkers, but alterations in proteome expression are more likely to reflect changes in tumour pathophysiology. In the past, clinical diagnostics have strongly relied on antibody-based detection strategies, but these methods carry certain limitations. Mass spectrometry (MS) is a powerful method that enables increasingly comprehensive insights into changes of the proteome to advance personalized medicine. In this review, recent improvements in MS-based clinical proteomics are highlighted with a focus on oncology. We will provide a detailed overview of clinically relevant samples types, as well as, consideration for sample preparation methods, protein quantitation strategies, MS configurations, and data analysis pipelines currently available to researchers. Critical consideration of each step is necessary to address the pressing clinical questions that advance cancer patient diagnosis and prognosis. While the majority of studies focus on the discovery of clinically-relevant biomarkers, there is a growing demand for rigorous biomarker validation. These studies focus on high-throughput targeted MS assays and multi-centre studies with standardized protocols. Additionally, improvements in MS sensitivity are opening the door to new classes of tumour-specific proteoforms including post-translational modifications and variants originating from genomic aberrations. Overlaying proteomic data to complement genomic and transcriptomic datasets forges the growing field of proteogenomics, which shows great potential to improve our understanding of cancer biology. Overall, these advancements not only solidify MS-based clinical proteomics’ integral position in cancer research, but also accelerate the shift towards becoming a regular component of routine analysis and clinical practice.

Clinical proteomics and mass spectrometry profiling for cancer detection

Recent advances in mass spectrometry based clinical proteomics: applications to cancer research

Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers

Recent advances in clinical proteomics using mass spectrometry

Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging: a review

Clinical potential of mass spectrometry-based proteogenomics

Clinical Proteomics-Driven Precision Medicine for Targeted Cancer Therapy: Current Overview and Future Perspectives

Diagnostic Proteomics: Serum Proteomic Patterns for the Detection of Early Stage Cancers.

From “Clinical Proteomics” to “Clinical Chemistry Proteomics”: considerations using quantitative mass-spectrometry as a model approach

Clinical applications of mass spectrometry‐based proteomics in cancer: where are we?

Mass Spectrometry-Assisted Gel-Based Proteomics In Cancer Biomarker Discovery: Approaches And Application

Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment.

Advances and Challenges in Liquid Chromatography-Mass Spectrometry-based Proteomics Profiling for Clinical Applications

A Cancer Immunoprofiling Strategy Using Mass Spectrometry Coupled with Bioorthogonal Cleavage

MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation

Proteomics in human cancer research

Applications of MALDI-TOF mass spectrometry in clinical proteomics

Application of Liquid Chip Time-of-flight Mass Spectrometry Technology Profiling in Tumor Clinical Research

Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry

A Scaled Proteomic Discovery Study for Prostate Cancer Diagnostic Markers Using ProteographTM and Trapped Ion Mobility Mass Spectrometry

Proteomics in prostate cancer biomarker discovery